Liquid biopsies, a non-invasive method, are reshaping oncology by allowing for early and accurate detection of cancer. As a key element in precision medicine, they identify cancer's early stages, detect residual disease, and guide treatment decisions, greatly enhancing patient outcomes. Advances in genomics also aid in identifying new cancer drivers and potential therapeutic targets. Despite these strides, achieving early and precise diagnosis remains a hurdle in cancer treatment. Liquid biopsies address this, improving patient adherence to follow-up tests and overcoming traditional biopsy shortcomings. The American Association for Cancer Research (AACR) is also actively supporting liquid biopsy research and cancer prevention strategies, aiming to better patient outcomes. In the future, liquid biopsies are expected to drastically alter cancer treatment approaches, bringing us closer to improving patient quality of life.
Full article here: https://medium.com/@lawsuithelpdesk/title-unveiling-the-power-of-liquid-biopsies-a-new-dawn-in-cancer-diagnosis-and-treatment-7783abc553ba
